BIO Bio-Rad Laboratories Inc

Price (delayed)

$567.92

Market cap

$16.95B

P/E Ratio

4.44

Dividend/share

N/A

EPS

$127.86

Enterprise value

$16.51B

Sector: Healthcare
Industry: Medical Devices

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights

The EPS has soared by 117% YoY and by 8% from the previous quarter
The net income has soared by 116% YoY and by 8% QoQ

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.84M
Market cap
$16.95B
Enterprise value
$16.51B
Valuations
Price to earnings (P/E)
4.44
Price to book (P/B)
1.71
Price to sales (P/S)
6.64
EV/EBIT
3.35
EV/EBITDA
3.35
EV/Sales
6.49
Earnings
Revenue
$2.55B
EBIT
$4.93B
EBITDA
$4.93B
Free cash flow
$476.48M
Per share
EPS
$127.86
Free cash flow per share
$16.01
Book value per share
$331.2
Revenue per share
$85.52
TBVPS
$419.28
Balance sheet
Total assets
$12.97B
Total liabilities
$3.09B
Debt
$225.69M
Equity
$9.88B
Working capital
$1.51B
Liquidity
Debt to equity
0.02
Current ratio
3.39
Quick ratio
2.24
Net debt/EBITDA
-0.09
Margins
EBITDA margin
193.6%
Gross margin
56.5%
Net margin
149.5%
Operating margin
16.1%
Efficiency
Return on assets
34.8%
Return on equity
47.1%
Return on invested capital
52%
Return on capital employed
39.9%
Return on sales
193.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
1.05%
1 week
-2.84%
1 month
-7.88%
1 year
46.87%
YTD
-2.58%
QTD
-2.58%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.55B
Gross profit
$1.44B
Operating income
$410.96M
Net income
$3.81B
Gross margin
56.5%
Net margin
149.5%
The net income has soared by 116% YoY and by 8% QoQ
The net margin has surged by 96% year-on-year
BIO's operating income has surged by 79% year-on-year and by 39% since the previous quarter
BIO's operating margin has surged by 63% year-on-year and by 30% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
4.44
P/B
1.71
P/S
6.64
EV/EBIT
3.35
EV/EBITDA
3.35
EV/Sales
6.49
The EPS has soared by 117% YoY and by 8% from the previous quarter
The price to earnings (P/E) is 95% lower than the 5-year quarterly average of 83.5 and 21% lower than the last 4 quarters average of 5.6
The equity has soared by 72% YoY and by 12% from the previous quarter
BIO's P/B is 10% below its 5-year quarterly average of 1.9
The stock's price to sales (P/S) is 75% more than its 5-year quarterly average of 3.8 and 13% more than its last 4 quarters average of 5.9
The revenue has grown by 10% YoY and by 7% from the previous quarter

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 96% YoY
The company's return on invested capital rose by 50% YoY but it fell by 5% QoQ
Bio-Rad Laboratories's ROA has increased by 47% YoY but it has decreased by 4.1% from the previous quarter
The ROE is up by 42% year-on-year but it is down by 6% since the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The total assets has soared by 62% year-on-year and by 8% since the previous quarter
The company's current ratio rose by 44% QoQ and by 41% YoY
The debt is 98% smaller than the equity
Bio-Rad Laboratories's debt to equity has plunged by 82% YoY and by 71% from the previous quarter
The equity has soared by 72% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.